PL3106176T3 - Związki glinu do stosowania w terapeutykach i szczepionkach - Google Patents

Związki glinu do stosowania w terapeutykach i szczepionkach

Info

Publication number
PL3106176T3
PL3106176T3 PL16183076T PL16183076T PL3106176T3 PL 3106176 T3 PL3106176 T3 PL 3106176T3 PL 16183076 T PL16183076 T PL 16183076T PL 16183076 T PL16183076 T PL 16183076T PL 3106176 T3 PL3106176 T3 PL 3106176T3
Authority
PL
Poland
Prior art keywords
vaccines
therapeutics
aluminium compounds
aluminium
compounds
Prior art date
Application number
PL16183076T
Other languages
English (en)
Inventor
Michael Möhlen
Michael Weber
Jürgen Wruss
Robert Schlegl
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47294919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3106176(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/054387 external-priority patent/WO2013135274A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of PL3106176T3 publication Critical patent/PL3106176T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL16183076T 2011-12-06 2012-12-06 Związki glinu do stosowania w terapeutykach i szczepionkach PL3106176T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11192230 2011-12-06
PCT/EP2012/054387 WO2013135274A1 (en) 2012-03-13 2012-03-13 Aluminium compounds for use in therapeutics and vaccines
EP16183076.5A EP3106176B1 (en) 2011-12-06 2012-12-06 Aluminium compounds for use in therapeutics and vaccines
EP12795830.4A EP2788023B1 (en) 2011-12-06 2012-12-06 Aluminium compounds for use in therapeutics and vaccines

Publications (1)

Publication Number Publication Date
PL3106176T3 true PL3106176T3 (pl) 2018-03-30

Family

ID=47294919

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16183076T PL3106176T3 (pl) 2011-12-06 2012-12-06 Związki glinu do stosowania w terapeutykach i szczepionkach
PL17185526.5T PL3269386T3 (pl) 2011-12-06 2012-12-06 Związki glinu do stosowania w środkach terapeutycznych i szczepionkach

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17185526.5T PL3269386T3 (pl) 2011-12-06 2012-12-06 Związki glinu do stosowania w środkach terapeutycznych i szczepionkach

Country Status (16)

Country Link
EP (5) EP3269386B1 (pl)
CY (1) CY1119927T1 (pl)
DE (1) DE202012012768U1 (pl)
DK (6) DK2788023T3 (pl)
ES (3) ES2647882T3 (pl)
FI (1) FI3785730T3 (pl)
HR (1) HRP20171871T1 (pl)
HU (1) HUE037325T2 (pl)
LT (1) LT3106176T (pl)
NO (1) NO3106176T3 (pl)
PL (2) PL3106176T3 (pl)
PT (2) PT3269386T (pl)
RS (1) RS56709B1 (pl)
SI (1) SI3106176T1 (pl)
SM (1) SMT201700607T1 (pl)
WO (1) WO2013083726A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
EP3188750B1 (en) 2014-09-03 2020-03-11 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
EP4253403A3 (en) 2015-12-23 2023-12-27 Valneva Austria GmbH Zika virus purification
DK3562503T3 (da) 2016-12-30 2025-05-26 Vaxcyte Inc Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
ES2957939T3 (es) 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
SG11202001161YA (en) 2017-09-21 2020-03-30 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CA3081581A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2020012037A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
CN114127101A (zh) 2019-05-20 2022-03-01 瓦尔尼瓦公司 用于治疗或预防呼吸道感染的亚单位疫苗
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
EP4114457A4 (en) * 2020-03-01 2023-08-09 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
US20230218740A1 (en) * 2020-03-01 2023-07-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
CN115698044A (zh) 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
EP4319804A2 (en) 2021-04-09 2024-02-14 Valneva SE Human metapneumo virus vaccine
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
EP4652265A1 (en) 2023-01-18 2025-11-26 Valneva Austria GmbH Process for virus production in a bioreactor
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4761372A (en) 1981-01-12 1988-08-02 New York University Mutant enterotoxin of E. coli
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5308835A (en) 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
AUPO264096A0 (en) 1996-09-30 1996-10-24 Mclaughlin Geosurveys Pty Ltd. Value improvement of clays
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
DK1604685T3 (da) 1997-08-28 2012-06-18 Cj Cheiljedang Corp Et svækket japansk encephalitisvirus
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
CA2437899C (en) 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20110189217A1 (en) * 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
CN101734698B (zh) 2009-09-08 2013-01-09 东北大学 一种由含铝物料制备氧化铝的方法
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines

Also Published As

Publication number Publication date
ES2647882T3 (es) 2017-12-27
DK2788023T3 (en) 2016-12-19
ES2930458T3 (es) 2022-12-13
FI3785730T3 (fi) 2024-05-06
EP2788023A1 (en) 2014-10-15
EP3106176A1 (en) 2016-12-21
PT3106176T (pt) 2017-12-20
HUE037325T2 (hu) 2018-08-28
NO3106176T3 (pl) 2018-03-10
CY1119927T1 (el) 2018-12-12
LT3106176T (lt) 2018-01-10
HRP20171871T1 (hr) 2018-01-12
SMT201700607T1 (it) 2018-01-11
EP3269386A1 (en) 2018-01-17
EP3106176B1 (en) 2017-10-11
EP4400115A2 (en) 2024-07-17
WO2013083726A1 (en) 2013-06-13
ES2987623T3 (es) 2024-11-15
DK3106176T3 (en) 2018-01-08
SI3106176T1 (en) 2018-04-30
DE202012012768U1 (de) 2014-01-21
EP3785730B1 (en) 2024-04-24
EP3785730A1 (en) 2021-03-03
EP3269386B1 (en) 2022-09-14
DK3269386T3 (da) 2022-10-24
PT3269386T (pt) 2022-12-05
EP2788023B1 (en) 2016-11-02
PL3269386T3 (pl) 2022-12-05
RS56709B1 (sr) 2018-03-30
EP4400115A3 (en) 2024-10-23
DK3785730T3 (da) 2024-05-06
DK201300194U1 (da) 2014-01-17
DK201300193U1 (da) 2014-01-17

Similar Documents

Publication Publication Date Title
SMT201700607T1 (it) Composti a base di alluminio per uso in agenti terapeutici ed in vaccini
EP2928562A4 (en) PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
GB201120993D0 (en) Novel compounds and their use in therapy
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
GB201111705D0 (en) Compounds and their use
EP2736329A4 (en) COMPOUNDS AND METHODS
SG10201606161UA (en) Albumin Formulation and Use
IL231082A (en) Pyrimido compounds - pyridazinone and their use
PL3701800T3 (pl) Zastosowanie
ZA201401527B (en) Improvements in lockers
GB201111630D0 (en) Novel compounds and their use
GB201218084D0 (en) Novel compounds and methods for use in medicine
GB2497288B (en) Improvements in or relating to stairlifts
GB201114448D0 (en) Compounds and their use
PL2591798T3 (pl) Szczepionka do zastosowania w immunoterapii nowotworów
EP2721788A4 (en) METHOD AND ARRANGEMENT FOR SENDING QUESTIONS
GB201103716D0 (en) Improvements in or relating to stairlifts
IL232809A0 (en) Carboxamides converted at position 2 in isothiazolopyridine and their use as medicinal preparations
GB201121833D0 (en) Aluminium compounds for use in therapeutics and vaccines
GB2491553B (en) Improvements in or relating to stairlifts
EP2723349A4 (en) MICROARN-31 COMPOSITIONS AND METHODS OF USE IN AUTOIMMUNE DISEASES
PL2688418T3 (pl) Bogata w stygmasterol kompozycja fitosterolowa i jej zastosowania
GB201104444D0 (en) Compounds and their use